Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification

Table 1 Patient characteristics

Variables	(n = 394)	95%CI
Gender
Male	51%	46-56
Female	49%	44-54
Nationality
Saudi	94%	91-96
Non-Saudi	6%	3.7-8.4
Environment
Urban	91.6%	88.7-94.5
Rural	8.3%	5.4-11.2
Mean BMI	22.6	22.5-22.7
Mean age (yr)	30.1	28.9-31.4
Mean duration of disease (yr)	8	7.3-8.5
Smoking
Smokers	7.8%	4.9-10.7
Non-Smokers	92.2%	89.2-95.1
Course
Infrequent	77.5%	73.2-82.2
Frequent	17.3%	13.3-21.5
Chronic	4.8%	2.4-7.1
Steroid use
Once	33.5%	28.7-39.1
Twice	10.8%	7.4-14.3
Three	8.3%	5.3-11.4
More than three times	8.6%	5.6-11.8
Never	37.5%	32.6-43.3
Number of relatives with CD
First degree	0.6%	0.2-1.5
Second degree	0.6%	0.2-1.5
Number of relatives with UC
First degree	7%	3.3-10.7
Second degree	1.8%	0.4-3.3
Number of relatives with IBDU
First degree	0.6%	0.2-1.5
Second degree	0.3%	0.3-0.9
Number of relatives with colorectal cancer
First degree	0.9%	0.1-2.0
Second degree	0.9%	0.1-2.0

BMI: Body Mass Index; CD: Crohn's disease; UC: Ulcerative colitis; IBDU: Inflammatory bowel disease unclassified; Infrequent relapser: Defined as patients with 1 or less relapses per year.

Table 2 Patients according to the Montreal classification

Variables	n = 394	95%CI
Age, Montréal classification
A1	7.3%	4.7-9.9
A2	68.4%	63.8-73.0
A3	24.2%	20.0-28.4
Extent, Montréal classification
E1	22.0%	17.4-26.5
E2	35.3 %	30-40.5
E3	42.7 %	37.3-48.5
Severity, Montréal classification
S0	51.4%	46.0-57.0
S1	16.6%	12.5-20.6
S2	23.4%	18.75-28.0
S3	8.6%	5.5-11.6

A1: Those with age of diagnosis at 16 years or younger; A2 and A3 for age of diagnosis at 17-40 years and > 40 years, respectively.

Table 3 Extraintestinal manifestations

Variables	n = 312	95%CI
PSC	0.9%	0.01-2.0
Venous thrombosis	1.9%	0.3-3.3
Eye manifestation	1.5%	0.1-2.9
Stomatitis	1.5%	0.1-2.9
Joint involvement	17.5%	10.4-24.5
Bone manifestation
Osteoporosis	17.1%	9.8-24.4
Osteopenia	30.5%	21.5-39.4
Skin manifestation	7.06%	4.2-9.8
Erythema nodosum	23.8%	3.9-43
Pyoderma gangraenosum	4.8%	0.1-14
Psoriasis	9.5%	0.1-23.4
Others	61.9%	39.2-84.5